FDA Grants Import Discretion of Bracco's Iodinated Contrast Medium

Bracco Diagnostics Inc. has announced that the U.S. Food and Drug Administration (FDA) granted import discretion of Iomeron (iomeprol injection) into the U.S. to address the ongoing iodinated contrast media shortage. The product addresses the need for the most advanced diagnostic imaging standards and will be temporarily available in the U.S. market starting at the end of August, 2022.

S-1

articles • APPLIED RADIOLOGY

Survey Reports Radiologist Input on Key Issues, MRI Contrast Agents

Siemens Announces FDA Clearance of Three New Cios Mobile C-arms

Short-, Mid-, and Long-term Strategies to Manage the Shortage of Iohexol

Bracco Diagnostics 00270131530 - McKesson Medical-Surgical

FDA Grants Import Discretion of Bracco's Iodinated Contrast Medium Iomeron (iomeprol injection) to Address Supply Shortages

Efficacy and Safety of Gadopiclenol with Contrast-enhanced MRI of the Central Nervous System Published

Generic, FDA approved contrast agent set to hit the market in wake of nationwide shortage